A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

Who May Qualify: - Be able and willing to provide written willing to sign a consent form. - Have a expected to live at least 3 months. - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Subjects with diagnosed by tissue sample (biopsy-confirmed) advanced/metastatic pancreatic ductal adenocarcinoma (PDAC), who have progressed on ≤2 prior lines of systemic therapy. - According to RECIST v1.1, there is at least one measurable lesion. - Has your organs (liver, kidneys, etc.) are working well enough based on blood tests. - All subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 90 days after the last dose of study treatment. - Able to to comply with all requirements of study participation (including all study procedures). Who Should NOT Join This Trial: - Except for PDAC, the subjects had other malignant tumors within the 5 years prior to enrollment. - There is central nervous system (CNS) metastasis, spinal cord compression, or meningeal metastasis. - There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage. - previous cancer treatment that works throughout the body (like chemotherapy) with either TGF-β inhibitors or anti-angiogenic agents. - There is a history of non infectious pneumonia that requires systemic glucocorticoid treatment. - History of severe bleeding tendency or coagulation dysfunction. - Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. - Pregnant or lactating female subject. Always talk to your doctor about whether this trial is right for you.